

## Prostatype Genomics AB publishes prospectus due to

### upcoming preferential rights issue of units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

**The subscription period in Prostatype Genomics AB ("Prostatype Genomics" or the "Company") preferential rights issue of units of approximately SEK 27.3 million (the "Rights Issue"), which is covered by cash pre-subscription commitments and guarantee commitments of a total of approximately SEK 22.1 million, corresponding to approximately 81 percent of the Rights Issue, commences on 21 May 2021. The Swedish Financial Authority ("SFSA") has today approved Prostatype Genomics' prospectus regarding the Rights Issue and the prospectus is now available at the Company's website, [www.prostatypegenomics.com](http://www.prostatypegenomics.com).**

### Prospectus

The prospectus that Prostatype Genomics has prepared in connection with Rights Issue of units has today been approved by the SFSA. The prospectus, containing complete terms and instructions, is available at Prostatype Genomics's website (<https://www.prostatypegenomics.com/>) and Nordic Issuing's website (<https://nordic-issuing.se/>). The prospectus will also be available at the website of the SFSA (<https://fi.se/>).

The prospectus has been prepared as an EU-Growth prospectus in accordance with article 15 in the Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The prospectus has been approved by the SFSA, which is the Swedish competent authority in accordance with the Prospectus Regulation, in accordance with article 20 in the Prospectus Regulation. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of Prostatype Genomics or as an endorsement of the quality of the shares that are the subject of the prospectus and does not indicate that the SFSA guarantees that the facts in the prospectus are correct or complete. Investors should make their own assessment as to the suitability of investing in the Rights Issue.

An English translation of the original prospectus in Swedish is available at the Company's website for information purposes only. In case of a discrepancy, the Swedish original will prevail.

### Summary of the Rights Issue

- Existing shareholders will receive one (1) unit right for each share held on the record date 19 May 2025. One (1) unit right entitles the holder to subscribe for one (1) unit in the Company.
- Each unit consists of four (4) new shares and three (3) warrants of series T05.

- The Rights Issue comprises a maximum of 6,835,213 units, corresponding to a maximum of 27,340,852 shares and 20,505,639 warrants of series TO5. Upon full subscription in the Rights Issue, Prostatype Genomics will initially receive approximately SEK 27.3 million before deduction of issue costs.
- One (1) warrant of series TO5 entitles the holder to subscribe for one (1) new share in the Company during the period 3 September 2025 to and including 17 September 2025 at an exercise price corresponding to 70% of the 20-day volume-weighted average price prior to the second day prior to the exercise period. However, no less than SEK 0.10 and no higher than SEK 1.50 per share.
- The last day of trading in Prostatype Genomics share including the right to receive unit rights in the Rights Issue is 15 May 2025. The shares are traded excluding the right to receive unit rights in the Rights issue from 16 May 2025.
- The subscription price in the Rights Issue is SEK 4.00 per unit, corresponding to SEK 1.00 per share. warrants of series TO5 are issued free of charge.
- The subscription period in the Rights Issue runs from 21 May 2025 to and including 4 June 2025.
- Warrants of series TO5 are expected to be admitted to trading on Nasdaq First North Growth Market in close connection with the registration of the Rights Issue with the Swedish Companies Registration Office and the conversion of BTU to ordinary shares and warrants.
- The Rights Issue is covered by pre-subscription commitments and guarantee commitments of a total of approximately 81 percent. The guarantee commitments consist partly of so-called top-down underwritings and partly of a so-called bottom underwritings.
- In order to secure the Company's liquidity needs until the Rights Issue has been completed, the Company obtained a bridge loan of SEK 5 million in April 2025 from Exelity AB, Buntel AB and Oliver Molse. The bridge loan shall be repaid in cash with the issue proceeds.
- In order to meet the interest for participating in the Rights Issue and thereby further strengthening the Company's financial position, the Board has been authorized by the annual general meeting to issue additional units through so-called over-allotment in the event of oversubscription of the Rights Issue. The authorization is limited to approximately 15 percent of the total amount of units in the Rights Issue and an issue in accordance with the authorization shall be made on corresponding terms as the Rights Issue.

**Indicative time plan for the Rights Issue**

- 16 May 2025: First day of trading in the share excluding the right to receive unit rights
- 19 May 2025: Record date
- 21-30 May 2025: Trading in unit rights
- 21 May 2025-4 June 2025: Subscription period
- 21 May 2025 - until approximately one week after the Rights Issue has been registered with the Swedish Company Registration Office (sw. Bolagsverket): Trading in BTU
- 5 June 2025: Announcement of press release with outcome of Rights Issue

**Advisors**

Prostatype Genomics has mandated Navia Corporate Finance AB and Gemstone Capital A/S as financial advisors, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as settlement agent in connection with the Rights Issue.

**For more information about the Rights Issue, please contact:**

Navia Corporate Finance AB

E-mail: [info@naviacf.se](mailto:info@naviacf.se)Website: [www.naviacorporatefinance.com](http://www.naviacorporatefinance.com)

or

Gemstone Capital ApS

E-mail: [info@gemstonecapital.com](mailto:info@gemstonecapital.com)Website: [www.gemstonecapital.com](http://www.gemstonecapital.com)**For more information about the Company, please contact:**

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

E-mail: [fredrik.rickman@prostatypegenomics.com](mailto:fredrik.rickman@prostatypegenomics.com)**Certified Adviser**

DNB Carnegie Investment Bank AB

Telephone: +46 (0)73 856 42 65

E-mail: [certifiedadviser@carnegie.se](mailto:certifiedadviser@carnegie.se)**About Prostatype Genomics**

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB. The Company's Certified Adviser is DNB Carnegie.

**Important information**

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for units in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics has published.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial

Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

**Forward-looking Statements**

This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.

Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.